Pyruvate kinase (PK) deficiency is a systemic and progressive disease characterized by lifelong chronic hemolysis.1,2
Confirm or rule out PK deficiency today to help prevent serious long-term complications, like iron overload.2,3
SEE THE RISKSMolly M.
Molly M.
Pyruvate kinase (PK) deficiency is a systemic and progressive disease characterized by lifelong chronic hemolysis.1,2
Confirm or rule out PK deficiency today to help prevent serious long-term complications, like iron overload.2,3
See the RisksSee the markers of chronic hemolysis that could lead to a PK deficiency diagnosis
GO TO DIAGNOSTIC PATHWAYGet information about the devastating long-term consequences of PK deficiency, as observed through two patient studies4,5
SEE THE DATAWatch PK deficiency experts discuss details about their experiences with the disease
HEAR FROM YOUR PEERSReferences: 1. Grace RF, Zanella A, Neufeld EJ, et al. Erythrocyte pyruvate kinase deficiency: 2015 status report. Am J Hematol. 2015;90(9):825-830. 2. Zanella A, Fermo E, Bianchi P, Valentini G. Red cell pyruvate kinase deficiency: molecular and clinical aspects. Br J Haematol. 2005;130(1):11-25. 3. Boscoe AN, Yan Y, Hedgeman E, et al. Comorbidities and complications in adults with pyruvate kinase deficiency. Poster presented at: The American Society of Hematology (ASH) Annual Meeting; December 7–10, 2019; Orlando, FL. 4. Higa S, Keapoletswe K, Cirneanu L, et al. The clinical characteristics and overall survival of patients with pyruvate kinase deficiency in the UK: a real-world study. Presented at: European Hematology Association (EHA) Hybrid Congress; June 8-11, 2023; Frankfurt, Germany, and Virtual. 5. Zagadailov E, Boscoe AN, Garcia-Horton V, et al. Mortality among veterans with a diagnosis of pyruvate kinase deficiency: a real-world study using US Veterans Health Administration data. Presented at: European Hematology Association (EHA) Virtual Congress; June 9-17, 2021.